Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models
Figure 2
Rh-endostatin decreases microvascular density (MVD) and promotes vessel normalization of A549 lung carcinoma.
A549 tumor-bearing mice were treated with rh-endostatin (5 mg/kg, s.c.) for consecutive 7 days with normal saline as control. On days 3, 6 and 9, mice (n = 4, each group and each time point) were sacrificed and tumor samples were stained by anti-CD31 antibody and anti-α-SMA antibody. A, typical fluorescence images of tumors showed CD31-positive endothelial cells (red), α-SMA positive pericytes (green) and merged images (orange) in A549 lung carcinoma in control group and rh-endostatin treated group on days 3, 6, and 9, respectively. B, columns represented microvascular densities at different time points in two groups. C, columns represented pericyte coverages at different time points in the two groups. Representative sections are shown from all groups with a magnification of 400×. Columns, mean; Bars, SE; *p<0.05, indicating significant difference.